GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs

Posted
GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. The post GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Pharma, antibody-targeted therapy conjugate, biopharma nl, cancer, colorectal cancer, Deals, GSK, Hutchmed, lung cancer, pancreatic cancer